Abstract: TH-PO234
Endotrophin as a Marker of Complications in a Type 2 Diabetes Cohort
Session Information
- Diabetic Kidney Disease: Clinical - I
November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Diabetic Kidney Disease
- 602 Diabetic Kidney Disease: Clinical
Authors
- Tougaard, Ninna Hahn, Steno Diabetes Center Copenhagen, Herlev, Capital Region, Denmark
- Møller, Alexandra L., Nordic Bioscience, Herlev, Denmark
- Rønn, Pernille Falberg, Steno Diabetes Center Copenhagen, Herlev, Capital Region, Denmark
- Hansen, Tine, Steno Diabetes Center Copenhagen, Herlev, Capital Region, Denmark
- Genovese, Federica, Nordic Bioscience, Herlev, Herlev , Denmark
- Karsdal, Morten Asser, Nordic Bioscience, Herlev, Herlev , Denmark
- Rasmussen, Daniel Guldager Kring, Nordic Bioscience, Herlev, Herlev , Denmark
- Rossing, Peter, Steno Diabetes Center Copenhagen, Herlev, Denmark
Background
Hyperglycemia-mediated tissue injury eventually leads to fibrosis affecting various organ systems. We investigated whether endotrophin, a profibrotic signaling molecule, reflecting collagen VI formation, in serum and urine was associated with risk of developing complications in an unselected population with type 2 diabetes.
Methods
Endotrophin was measured by the PRO-C6 ELISA in serum and urine from 774 persons with type 2 diabetes recruited between 2012 and 2016. Urinary values were normalized to urine creatinine levels. Outcomes were identified through national registers and medical records and included a composite kidney endpoint (≥40% decline in kidney function or kidney failure), first major adverse cardiovascular event (MACE), all-cause mortality, progression of albuminuria, incident heart failure and sight-threatening eye disease. Cox proportional hazards models adjusted for conventional risk factors were applied.
Results
The cohort included 254 (33%) females, mean ±SD age was 65 ±12 years, diabetes duration 17 ±8.8 years, eGFR 76 ±24 ml/min/1.73m2 and median [Q1:Q3] urinary albumin excretion was 12.5 [5.5:73.5] mg/g or g/24h. Depending on outcome, median follow-up ranged from 3.0 to 6.0 years. A doubling of serum endotrophin was independently associated with the composite kidney endpoint, first MACE, all-cause mortality and incident heart failure, but not with progression of albuminuria or incident sight-threatening eye disease (Table). A doubling of urine endotrophin was independently associated with progression of albuminuria and incident heart failure, but not with the other outcomes (Table).
Conclusion
Serum endotrophin was a risk marker for mortality, kidney and cardiovascular complications in type 2 diabetes. Urine endotrophin was a risk marker for progression of albuminuria and incident heart failure.
Associations between endotrophin and complications incidence estimated by Cox proportional-hazards model